Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of GSK576389A vs Fluarix in Older Adults Previously Vaccinated
NCT00529516Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2007
- Primary completion
- Dec 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
Phase 3, double-blind trial of GSK576389A in influenza (3 arms), sponsored by GSK. Primary endpoints: Number of Subjects Reporting Any and Grade 3 Solicited Local Adverse Events at 7 days, Number of Subjects Reporting Any, Grade 3 and Related Solicited General Adverse Events at 7 days and 1 more. Started Oct 2007; status: completed.
02
Drugs
GSK576389A
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00529516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00529516.